View Post

TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

In Clinical Studies News by Barbara Jacoby

Source: Translational Research in Oncology From: finance.yahoo.com Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment completion in coopERA Breast Cancer (WO42133/TRIO038), a Phase 2 randomized, multi-center, open-label clinical trial of giredestrant (GDC-9545) sponsored by F. Hoffmann-La Roche. This comes shortly after completion of the planned study interim analysis provided encouraging results and supported continuation …

View Post

FDA Approves Dose-Escalation Label Update for Neratinib in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com THe FDA has approved a labeling supplement to the US prescribing information for neratinib that includes the dose-escalated use of the agent in patients with HER2-positive breast cancer, as examined in the phase 2 CONTROL trial, and the new 133-count commercial Nerlynx SKU. The FDA has approved a labeling supplement to the US prescribing information …

View Post

De-escalated neoadjuvant paclitaxel, dual HER2 blockade effective in breast cancer subtype

In Clinical Studies News by Barbara Jacoby

By: Ryan Lawrence From: healio.com A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus weekly paclitaxel demonstrated high efficacy among patients with HER2-positive, hormone receptor-negative early breast cancer. Researchers presented the first survival data from the randomized, phase 2 WSG-ADAPT-HR-/HER2+ trial — part of the ADAPT umbrella protocol — during the virtual ASCO Annual …

View Post

UVA Cancer Center to Expand Use of Theraclion’s HIFU System in Cancer Treatment Research

In Clinical Studies News by Barbara Jacoby

From: businesswire.com HERACLION (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME eligible), an innovative company specialized in echotherapy treatment (using High Intensity Focused Ultrasound or HIFU), announces a phase-2 collaboration with the University of Virginia Cancer Center. This extends the investigation of combining HIFU with immunotherapy from late-stage to that of early-stage breast cancer. If successful, such a protocol could open a new …

View Post

Alpelisib Plus Fulvestrant Shows Activity Following CDK4/6 Inhibition for HR+/HER– Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Matthew Fowler From: cancernetwork.com The combination of alpelisib and fulvestrant maintained a tolerable safety profile for patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced breast cancer who progressed after previous treatment with a CDK4/6 inhibitor. Alpelisib (Piqray) plus fulvestrant (Faslodex) produced activity while maintaining a tolerable safety profile for patients with PIK3CA-mutated, hormone receptor­–positive, HER2-negative advanced breast cancer who progressed …

View Post

Dr. Gradishar on Pretreatment With Cetirizine to Prevent Infusion Reactions in Breast Cancer and Other Malignancies

In Clinical Studies News by Barbara Jacoby

By: William J. Gradishar, MD   From: onclive.com William Gradishar, MD, discusses the efficacy of pretreatment with intravenous cetirizine in the prevention of infusion reactions in patients with breast cancer and other malignancies. William Gradishar, MD, the chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, and a professor of medicine (hematology and oncology) at …

View Post

Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics

In Clinical Studies News by Barbara Jacoby

Source: Newsfile Corp. From: finance.yahoo.com – The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment – Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 months Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) (“Portage” or the “Company”) a clinical stage immuno-oncology company accelerating research and …

View Post

Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors

In Clinical Studies News by Barbara Jacoby

By: Gina Mauro From: onclive.com Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel. Intravenous (IV) cetirizine (Quzyttir) showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions (IRs) in patients with cancer who are undergoing treatment with an …

View Post

Less Diarrhea Seen When Neratinib Given in Dose-Escalated Fashion for Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Christina Bennett, MS From: cancertherapyadvisor.com Administering neratinib in a dose-escalated fashion with optional loperamide was found to reduce the incidence of severe diarrhea in patients with HER2-positive, early-stage breast cancer, according to data from the phase 2 CONTROL trial reported at the 17th St. Gallen International Breast Cancer Conference 2021. The CONTROL trial (ClinicalTrials.gov Identifier: NCT02400476) enrolled 563 patients …

View Post

Veru touts novel breast cancer treatment strategy as drug nears phase 3

In Clinical Studies News by Barbara Jacoby

By: Angus Liu From: fiercebiotech.com Hormone therapies, or endocrine therapies, are widely used to treat breast cancer that is estrogen receptor (ER)-positive, but resistance is a common problem. That has sparked interest in drugs targeting the androgen receptor (AR). But the role of AR in ER-positive disease remains unclear, leading to the development of both AR agonists and antagonists. Now …